These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 27540771)

  • 21. Multiple imputation analysis of case-cohort studies.
    Marti H; Chavance M
    Stat Med; 2011 Jun; 30(13):1595-607. PubMed ID: 21351290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A note on dichotomization of continuous response variable in the presence of contamination and model misspecification.
    Shentu Y; Xie M
    Stat Med; 2010 Sep; 29(21):2200-14. PubMed ID: 20812301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimating treatment efficacy over time: a logistic regression model for binary longitudinal outcomes.
    Choi L; Dominici F; Zeger SL; Ouyang P
    Stat Med; 2005 Sep; 24(18):2789-805. PubMed ID: 16134133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimation of multiple response rates in phase II clinical trials with missing observations.
    Chang M
    J Biopharm Stat; 2009 Sep; 19(5):791-802. PubMed ID: 20183444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Robust Mantel-Haenszel test under genetic model uncertainty allowing for covariates in case-control association studies.
    Zang Y; Fung WK
    Genet Epidemiol; 2011 Nov; 35(7):695-705. PubMed ID: 22009791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Doubly robust estimation in missing data and causal inference models.
    Bang H; Robins JM
    Biometrics; 2005 Dec; 61(4):962-73. PubMed ID: 16401269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Double robust and efficient estimation of a prognostic model for events in the presence of dependent censoring.
    Schnitzer ME; Lok JJ; Bosch RJ
    Biostatistics; 2016 Jan; 17(1):165-77. PubMed ID: 26224070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estimation of the risk difference under a noncompliance randomized clinical trial with missing outcomes.
    Lui KJ
    J Biopharm Stat; 2008; 18(2):273-92. PubMed ID: 18327721
    [TBL] [Abstract][Full Text] [Related]  

  • 29. On responder analyses in the framework of within subject comparisons - considerations and two case studies.
    Kunz M
    Stat Med; 2014 Jul; 33(17):2939-52. PubMed ID: 24652819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of variance-function misspecification in analysis of longitudinal data.
    Wang YG; Lin X
    Biometrics; 2005 Jun; 61(2):413-21. PubMed ID: 16011687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Doubly robust estimators of causal exposure effects with missing data in the outcome, exposure or a confounder.
    Williamson EJ; Forbes A; Wolfe R
    Stat Med; 2012 Dec; 31(30):4382-400. PubMed ID: 23086504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Construction of group sequential designs in clinical trials on the basis of detectable treatment differences.
    Schäfer H; Müller HH
    Stat Med; 2004 May; 23(9):1413-24. PubMed ID: 15116350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparisons of methods for analysis of repeated binary responses with missing data.
    Frank Liu G; Zhan X
    J Biopharm Stat; 2011 May; 21(3):371-92. PubMed ID: 21442514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estimators of the local false discovery rate designed for small numbers of tests.
    Padilla M; Bickel DR
    Stat Appl Genet Mol Biol; 2012 Oct; 11(5):4. PubMed ID: 23079518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and analysis of group sequential logrank tests in maximum duration versus information trials.
    Kim K; Boucher H; Tsiatis AA
    Biometrics; 1995 Sep; 51(3):988-1000. PubMed ID: 7548714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of responder-based endpoints: improving power through utilising continuous components.
    Wason J; McMenamin M; Dodd S
    Trials; 2020 May; 21(1):427. PubMed ID: 32450909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Marginal analysis of incomplete longitudinal binary data: a cautionary note on LOCF imputation.
    Cook RJ; Zeng L; Yi GY
    Biometrics; 2004 Sep; 60(3):820-8. PubMed ID: 15339307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A mixture model using likelihood-based and Bayesian approaches for identifying responders and non-responders in longitudinal clinical trials.
    He J; Entsuah R
    Pharm Stat; 2014; 13(5):327-36. PubMed ID: 25182571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets.
    Siddiqui O; Hung HM; O'Neill R
    J Biopharm Stat; 2009; 19(2):227-46. PubMed ID: 19212876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimation and comparison of changes in the presence of informative right censoring: conditional linear model.
    Wu MC; Bailey KR
    Biometrics; 1989 Sep; 45(3):939-55. PubMed ID: 2486189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.